Overview
Pegargiminase is an anticancer agent.
Background
Pegargiminase is an anticancer agent.
Indication
Investigated for use/treatment in melanoma and hepatocellular carcinoma.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2023/10/17 | Phase 1 | Recruiting | |||
2023/09/13 | Phase 2 | Recruiting | Chang Gung Memorial Hospital | ||
2023/08/23 | Phase 1 | Withdrawn | |||
2023/05/06 | Phase 2 | Recruiting | Polaris Group | ||
2023/04/25 | Phase 2 | Withdrawn | |||
2022/11/15 | Phase 1 | Recruiting | |||
2022/04/08 | Phase 3 | Recruiting | Polaris Group | ||
2021/08/12 | Phase 1 | Recruiting | Polaris Group | ||
2020/10/14 | Phase 2 | Recruiting | Polaris Group | ||
2019/05/31 | Phase 2 | Recruiting | Global Coalition for Adaptive Research |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||